Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Blueprint Medicines Corporation
EIR
•Blueprint Medicines Corporation•September 5, 2019

Blueprint Medicines Corporation – FDA EIR, Sep 5, 2019

Record Details

A comprehensive FDA surveillance inspection of Blueprint Medicines Corporation was conducted from August 28 to September 5, 2019. This routine Prescription Drug User Fee (PDUFA) data integrity sponsor inspection, the first for the company, evaluated Blueprint's oversight of clinical study protocol BLU-285-1101, an investigational drug study supporting IND 125379 and NDA 212608. The inspection adhered to Compliance Program 7348.810, which governs sponsors, contract research organizations, and monitors. Although no formal FDA Form 483 (Inspectional Observations) was issued, the inspection identified several key issues discussed with management. These included the approval of critical study plans, such as the monitoring plan and eCRF Completion Guidelines, occurring after the first study participant had already commenced treatment. Additionally, the inspection highlighted challenges in confirming that Clinical Research Associates received adequate protocol and project-specific training prior to conducting monitoring visits. Most notably, Electronic Case Report Forms (eCRFs) submitted to the FDA as part of the NDA package did not contain adverse events that had been reported and subsequently deleted by clinical sites. Regarding corrective actions, company management did not provide specific responses to the observations about delayed plan approvals or CRA training documentation. However, in response to the eCRF data integrity concern, Blueprint plans to contact the FDA to discuss regenerating and resubmitting eCRFs that fully include all previously deleted adverse event information.

Company
Blueprint Medicines Corporation
Inspection date
September 5, 2019
Product type
drugs
Office
New England District Office
People
  • Sherwin Sattarzadeh (company_representative)
  • Jeffrey Albers (company_representative)
  • Vasu Miduturu (company_representative)
  • Tuan Dong Si (company_representative)
  • Michael Bauer (company_representative)
View Company Profile

ID · be46fc26-3062-46d6-b384-3854afbd33cc

Violation Codes3
21 CFR 21121 CFR 312.75(c)21 CFR 312

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Blueprint Medicines Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.